Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anecortave Acetate for AMD Prevention in Singapore
NCT00333216Phase 3Terminated
- Sponsor
- Alcon Inc.
- Start
- May 2005
- Primary completion
- Dec 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anecortave in exudative age-related macular degeneration (3 arms), sponsored by Alcon Inc. Primary endpoint: Proportion of patients with sight-threatening CNV in study eye at Month 48. Started May 2005; status: terminated.
02
Drugs
anecortave
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT00333216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00333216.